Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Douching, Talc Use, and Risk for Ovarian Cancer and Conditions Related to Genital Tract Inflammation.

Gabriel IM, Vitonis AF, Welch WR, Titus L, Cramer DW.

Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1835-1844. doi: 10.1158/1055-9965.EPI-19-0375. Epub 2019 Aug 27.

PMID:
31455671
2.

Migration of Talc From the Perineum to Multiple Pelvic Organ Sites.

McDonald SA, Fan Y, Welch WR, Cramer DW, Godleski JJ.

Am J Clin Pathol. 2019 Oct 7;152(5):590-607. doi: 10.1093/ajcp/aqz080.

PMID:
31305893
3.

Correlative polarizing light and scanning electron microscopy for the assessment of talc in pelvic region lymph nodes.

McDonald SA, Fan Y, Welch WR, Cramer DW, Stearns RC, Sheedy L, Katler M, Godleski JJ.

Ultrastruct Pathol. 2019;43(1):13-27. doi: 10.1080/01913123.2019.1593271. Epub 2019 Mar 21.

PMID:
30898001
4.

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE.

Int J Gynecol Pathol. 2019 May;38(3):230-240. doi: 10.1097/PGP.0000000000000513.

PMID:
29750700
5.

Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.

Yang J, Zhou Y, Ng SK, Huang KC, Ni X, Choi PW, Hasselblatt K, Muto MG, Welch WR, Berkowitz RS, Ng SW.

BMC Cancer. 2017 Jun 17;17(1):422. doi: 10.1186/s12885-017-3417-z.

6.

Correction: Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells.

Zhang Y, Kwok JS, Choi PW, Liu M, Yang J, Singh M, Ng SK, Welch WR, Muto MG, Tsui SK, Sugrue SP, Berkowitz RS, Ng SW.

Oncotarget. 2017 Feb 14;8(7):12533. doi: 10.18632/oncotarget.15321. No abstract available.

7.

Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.

Huang KC, Yang J, Ng MC, Ng SK, Welch WR, Muto MG, Berkowitz RS, Ng SW.

Eur J Cancer. 2016 Nov;67:152-163. doi: 10.1016/j.ejca.2016.08.007. Epub 2016 Sep 24.

8.

Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery?

Esselen KM, Terry KL, Samuel A, Elias KM, Davis M, Welch WR, Muto MG, Ng SW, Berkowitz RS.

Gynecol Oncol. 2016 Aug;142(2):255-60. doi: 10.1016/j.ygyno.2016.05.036. Epub 2016 Jun 3.

PMID:
27261327
9.

Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells.

Zhang Y, Kwok JS, Choi PW, Liu M, Yang J, Singh M, Ng SK, Welch WR, Muto MG, Tsui SK, Sugrue SP, Berkowitz RS, Ng SW.

Oncotarget. 2016 Mar 8;7(10):11397-411. doi: 10.18632/oncotarget.7242. Erratum in: Oncotarget. 2017 Feb 14;8(7):12533.

10.

Pore diameter effects on phase behavior of a gas condensate in graphitic one-and two-dimensional nanopores.

Welch WR, Piri M.

J Mol Model. 2016 Jan;22(1):22. doi: 10.1007/s00894-015-2894-8. Epub 2016 Jan 5.

PMID:
26733485
11.

The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States.

Cramer DW, Vitonis AF, Terry KL, Welch WR, Titus LJ.

Epidemiology. 2016 May;27(3):334-46. doi: 10.1097/EDE.0000000000000434.

12.

Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells.

Choi PW, Yang J, Ng SK, Feltmate C, Muto MG, Hasselblatt K, Lafferty-Whyte K, JeBailey L, MacConaill L, Welch WR, Fong WP, Berkowitz RS, Ng SW.

Oncotarget. 2016 Jan 26;7(4):4110-21. doi: 10.18632/oncotarget.6588.

13.

Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.

Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, Cramer DW.

Gynecol Oncol. 2014 Mar;132(3):542-50. doi: 10.1016/j.ygyno.2014.01.026. Epub 2014 Jan 23.

14.

Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Müllerian antigens.

Esselen KM, Ng SK, Hua Y, White M, Jimenez CA, Welch WR, Drapkin R, Berkowitz RS, Ng SW.

Gynecol Oncol. 2014 Feb;132(2):316-21. doi: 10.1016/j.ygyno.2013.12.007. Epub 2013 Dec 13.

PMID:
24333360
15.

Insight into the packing pattern of β2 fibrils: a model study of glutamic acid rich oligomers with 13C isotopic edited vibrational spectroscopy.

Chi H, Welch WR, Kubelka J, Keiderling TA.

Biomacromolecules. 2013 Nov 11;14(11):3880-91. doi: 10.1021/bm401015f. Epub 2013 Oct 9.

PMID:
24053614
16.

Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.

Cramer DW, Williams K, Vitonis AF, Yamamoto HS, Stuebe A, Welch WR, Titus L, Fichorova RN.

Cancer Causes Control. 2013 Nov;24(11):1911-23. doi: 10.1007/s10552-013-0266-1. Epub 2013 Aug 8.

17.
18.

Structural analyses of experimental 13C edited amide I' IR and VCD for peptide β-sheet aggregates and fibrils using DFT-based spectral simulations.

Welch WR, Keiderling TA, Kubelka J.

J Phys Chem B. 2013 Sep 12;117(36):10359-69. doi: 10.1021/jp405613r. Epub 2013 Aug 27.

PMID:
23924239
19.

Endometriosis-associated ovarian cancer: a review of pathogenesis.

Worley MJ, Welch WR, Berkowitz RS, Ng SW.

Int J Mol Sci. 2013 Mar 6;14(3):5367-79. doi: 10.3390/ijms14035367.

20.

C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.

Barroilhet L, Yang J, Hasselblatt K, Paranal RM, Ng SK, Rauh-Hain JA, Welch WR, Bradner JE, Berkowitz RS, Ng SW.

Oncogene. 2013 Aug 15;32(33):3896-903. doi: 10.1038/onc.2012.380. Epub 2012 Sep 3.

PMID:
22945647
21.

DFT-based simulations of amide I' IR spectra of a small protein in solution using empirical electrostatic map with a continuum solvent model.

Welch WR, Kubelka J.

J Phys Chem B. 2012 Sep 6;116(35):10739-47. doi: 10.1021/jp305387x. Epub 2012 Aug 28.

PMID:
22891757
22.

Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures.

Saw YT, Yang J, Ng SK, Liu S, Singh S, Singh M, Welch WR, Tsuda H, Fong WP, Thompson D, Vasiliou V, Berkowitz RS, Ng SW.

BMC Cancer. 2012 Aug 1;12:329.

23.

Casein kinase I epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells.

Rodriguez N, Yang J, Hasselblatt K, Liu S, Zhou Y, Rauh-Hain JA, Ng SK, Choi PW, Fong WP, Agar NY, Welch WR, Berkowitz RS, Ng SW.

EMBO Mol Med. 2012 Sep;4(9):952-63. doi: 10.1002/emmm.201101094. Epub 2012 Jun 18.

24.

Differential hRad17 expression by histologic subtype of ovarian cancer.

Young JL, Koon EC, Kwong J, Welch WR, Muto MG, Berkowitz RS, Mok SC.

J Ovarian Res. 2011 Mar 30;4(1):6. doi: 10.1186/1757-2215-4-6.

25.

C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.

Gao Z, Xu X, McClane B, Zeng Q, Litkouhi B, Welch WR, Berkowitz RS, Mok SC, Garner EI.

Clin Cancer Res. 2011 Mar 1;17(5):1065-74. doi: 10.1158/1078-0432.CCR-10-1644. Epub 2010 Dec 1.

26.

Correlates of the preoperative level of CA125 at presentation of ovarian cancer.

Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, Berkowitz RS.

Gynecol Oncol. 2010 Dec;119(3):462-8. doi: 10.1016/j.ygyno.2010.08.028. Epub 2010 Sep 17.

27.

Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.

Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC.

Gynecol Oncol. 2010 Oct;119(1):114-20. doi: 10.1016/j.ygyno.2010.05.029. Epub 2010 Jul 8.

28.

A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ.

Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.

29.

Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, Vitonis A, Wang K, McLachlan GJ, Caiazzo RJ Jr, Liu BC, Welch WR, Cramer DW, Berkowitz RS, Ng SW.

Eur J Cancer. 2010 Jan;46(1):170-9. doi: 10.1016/j.ejca.2009.10.003.

30.

RUNX3 protein is overexpressed in human epithelial ovarian cancer.

Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS, Mok SC.

Gynecol Oncol. 2009 Feb;112(2):325-30. doi: 10.1016/j.ygyno.2008.09.006. Epub 2008 Oct 19.

PMID:
18937968
31.

Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.

Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK.

Neoplasia. 2008 Sep;10(9):964-72.

32.

AAOMP case challenge: a nodule of the palate.

Eslami B, Lerman MA, Woo SB, Treister NS, Welch WR.

J Contemp Dent Pract. 2008 May 1;9(4):124-8. No abstract available.

PMID:
18473036
33.

Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.

Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC.

Gynecol Oncol. 2008 May;109(2):234-9. doi: 10.1016/j.ygyno.2008.01.031. Epub 2008 Mar 10.

PMID:
18331757
34.

Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.

Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC.

Clin Cancer Res. 2008 Feb 1;14(3):764-71. doi: 10.1158/1078-0432.CCR-07-0856.

35.

Etiology and pathogenesis of epithelial ovarian cancer.

Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK.

Dis Markers. 2007;23(5-6):367-76. Review.

36.

Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.

Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):976-84. Epub 2007 Nov 16.

PMID:
18021219
37.

Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc.

Cramer DW, Welch WR, Berkowitz RS, Godleski JJ.

Obstet Gynecol. 2007 Aug;110(2 Pt 2):498-501.

PMID:
17666642
38.

Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.

Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC.

J Clin Oncol. 2007 Jun 1;25(16):2281-7. Erratum in: J Clin Oncol. 2007 Jul 20;25(21):3184.

PMID:
17538174
39.

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.

Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC.

Gynecol Oncol. 2007 Aug;106(2):311-7. Epub 2007 May 25.

40.

The president and the pheochromocytoma.

Messerli FH, Loughlin KR, Messerli AW, Welch WR.

Am J Cardiol. 2007 May 1;99(9):1325-9. Epub 2007 Mar 16.

PMID:
17478167
41.

Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.

Litkouhi B, Kwong J, Lo CM, Smedley JG 3rd, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, Berkowitz RS, Mok SC, Garner EI.

Neoplasia. 2007 Apr;9(4):304-14.

42.

Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation.

Chang T, Husain AN, Colby T, Taxy JB, Welch WR, Cheung OY, Early A, Travis W, Krausz T.

Am J Surg Pathol. 2007 Apr;31(4):562-8.

PMID:
17414103
43.

Large calcifications in ovaries otherwise normal on ultrasound.

Brown DL, Laing FC, Welch WR.

Ultrasound Obstet Gynecol. 2007 Apr;29(4):438-42.

44.

Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.

Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):30-5.

45.

Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC.

Neoplasia. 2006 Apr;8(4):268-78.

46.

Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.

Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):690-700.

47.

Selenium binding protein 1 in ovarian cancer.

Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW.

Int J Cancer. 2006 May 15;118(10):2433-40.

48.

Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas.

Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC.

Clin Cancer Res. 2005 Nov 1;11(21):7651-7.

49.

Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.

Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8.

50.

Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.

Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1125-31.

Supplemental Content

Loading ...
Support Center